$50.01
0.06% yesterday
Nasdaq, Dec 24, 07:47 pm CET
ISIN
US0327241065
Symbol
ANAB

AnaptysBio, Inc. Target price 2025 - Analyst rating & recommendation

AnaptysBio, Inc. Classifications & Recommendation:

Buy
84%
Hold
16%

AnaptysBio, Inc. Price Target

Target Price $63.75
Price $50.01
Potential
Number of Estimates 14
14 Analysts have issued a price target AnaptysBio, Inc. 2026 . The average AnaptysBio, Inc. target price is $63.75. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 19 analysts: 16 Analysts recommend AnaptysBio, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AnaptysBio, Inc. stock has an average upside potential 2026 of . Most analysts recommend the AnaptysBio, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 91.28 214.92
431.93% 135.45%
EBITDA Margin -125.26% -3.80%
86.26% 96.97%
Net Margin -159.10% -16.25%
83.31% 89.79%

13 Analysts have issued a sales forecast AnaptysBio, Inc. 2025 . The average AnaptysBio, Inc. sales estimate is

$215m
Unlock
. This is
26.82% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$242m 42.87%
Unlock
, the lowest is
$159m 6.32%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $91.3m 431.93%
2025
$215m 135.45%
Unlock
2026
$136m 36.56%
Unlock
2027
$191m 39.94%
Unlock
2028
$292m 53.25%
Unlock
2029
$355m 21.55%
Unlock
2030
$544m 52.93%
Unlock
2031
$706m 29.92%
Unlock
2032
$876m 24.02%
Unlock

4 Analysts have issued an AnaptysBio, Inc. EBITDA forecast 2025. The average AnaptysBio, Inc. EBITDA estimate is

$-8.2m
Unlock
. This is
70.96% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$11.6m 141.10%
Unlock
, the lowest is
$-26.5m 5.84%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-114m 26.90%
2025
$-8.2m 92.86%
Unlock
2026
$12.8m 256.25%
Unlock
2027
$-44.4m 448.00%
Unlock

EBITDA Margin

2024 -125.26% 86.26%
2025
-3.80% 96.97%
Unlock
2026
9.35% 346.05%
Unlock
2027
-23.26% 348.77%
Unlock

13 AnaptysBio, Inc. Analysts have issued a net profit forecast 2025. The average AnaptysBio, Inc. net profit estimate is

$-34.9m
Unlock
. This is
58.75% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-14.2m 83.23%
Unlock
, the lowest is
$-84.9m 0.28%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-145m 11.24%
2025
$-34.9m 75.96%
Unlock
2026
$-126m 260.78%
Unlock
2027
$-140m 10.83%
Unlock
2028
$-87.8m 37.07%
Unlock
2029
$-43.7m 50.28%
Unlock
2030
$101m 330.30%
Unlock
2031
$204m 103.22%
Unlock
2032
$300m 47.01%
Unlock

Net Margin

2024 -159.10% 83.31%
2025
-16.25% 89.79%
Unlock
2026
-92.38% 468.49%
Unlock
2027
-73.16% 20.81%
Unlock
2028
-30.04% 58.94%
Unlock
2029
-12.29% 59.09%
Unlock
2030
18.50% 250.53%
Unlock
2031
28.94% 56.43%
Unlock
2032
34.31% 18.56%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.12 -1.27
15.79% 75.20%
P/E negative
EV/Sales 6.83

13 Analysts have issued a AnaptysBio, Inc. forecast for earnings per share. The average AnaptysBio, Inc. EPS is

$-1.27
Unlock
. This is
56.36% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.51 82.47%
Unlock
, the lowest is
$-3.08 5.84%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.12 15.79%
2025
$-1.27 75.20%
Unlock
2026
$-4.57 259.84%
Unlock
2027
$-5.06 10.72%
Unlock
2028
$-3.18 37.15%
Unlock
2029
$-1.58 50.31%
Unlock
2030
$3.65 331.01%
Unlock
2031
$7.41 103.01%
Unlock
2032
$10.89 46.96%
Unlock

P/E ratio

Current -17.19 576.78%
2025
-39.50 129.84%
Unlock
2026
-10.95 72.28%
Unlock
2027
-9.88 9.77%
Unlock
2028
-15.70 58.91%
Unlock
2029
-31.58 101.15%
Unlock
2030
13.71 143.41%
Unlock
2031
6.75 50.77%
Unlock
2032
4.59 32.00%
Unlock

Based on analysts' sales estimates for 2025, the AnaptysBio, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 8.66 3,836.36%
2025
6.83 21.15%
Unlock
2026
10.76 57.64%
Unlock
2027
7.69 28.54%
Unlock
2028
5.02 34.75%
Unlock
2029
4.13 17.73%
Unlock
2030
2.70 34.61%
Unlock
2031
2.08 23.03%
Unlock
2032
1.68 19.37%
Unlock

P/S ratio

Current 8.17 5.51%
2025
6.44 21.15%
Unlock
2026
10.16 57.63%
Unlock
2027
7.26 28.54%
Unlock
2028
4.74 34.75%
Unlock
2029
3.90 17.73%
Unlock
2030
2.55 34.61%
Unlock
2031
1.96 23.03%
Unlock
2032
1.58 19.37%
Unlock

Current AnaptysBio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Barclays
Locked
Locked
Locked Dec 17 2025
Stifel
Locked
Locked
Locked Dec 11 2025
Wedbush
Locked
Locked
Locked Nov 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 24 2025
Barclays
Locked
Locked
Locked Nov 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 11 2025
Truist Securities
Locked
Locked
Locked Nov 10 2025
Analyst Rating Date
Locked
Barclays:
Locked
Locked
Dec 17 2025
Locked
Stifel:
Locked
Locked
Dec 11 2025
Locked
Wedbush:
Locked
Locked
Nov 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 24 2025
Locked
Barclays:
Locked
Locked
Nov 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 11 2025
Locked
Truist Securities:
Locked
Locked
Nov 10 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today